Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study-Reference-Cited by-同舟云学术

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study

Published:2010-10-26 Issue:10 Volume:4 Page:e855
ISSN:1935-2735
Container-title:PLoS Neglected Tropical Diseases
language:en
Short-container-title:PLoS Negl Trop Dis

Author:

Musa Ahmed M.,Younis Brima,Fadlalla Ahmed,Royce Catherine,Balasegaram Manica,Wasunna Monique,Hailu Asrat,Edwards Tansy,Omollo Raymond,Mudawi Mahmoud,Kokwaro Gilbert,El-Hassan Ahmed,Khalil Eltahir

Publisher

Public Library of Science (PLoS)

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference16 articles.

1. Leishmaniasis. Public health aspects and control.;P Desjeux;Clin Dermatol,1996

2. Leishmaniasis.,2009

3. Drug resistance in leishmaniasis.;SL Croft;Clin Microbiol Rev,2006

4. Sodium stibogluconate cardiotoxicity and safety of generics.;S Rijal;Trans R Soc Trop Med Hyg,2003

5. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.;CP Thakur;Ann Trop Med Parasitol,1998

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1;PLOS Pathogens;2024-07-11

2. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate;PLOS Neglected Tropical Diseases;2024-05-20

3. In Vivo Bioluminescence Imaging Reveals Differences in Leishmania infantum Parasite Killing Kinetics by Antileishmanial Reference Drugs;ACS Infectious Diseases;2024-05-11

4. Identification of FDA-approved drugs that induce heart regeneration in mammals;Nature Cardiovascular Research;2024-03-11

5. The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis;Pharmaceutics;2024-02-04